Abstract:Protein phosphorylation is the most significant post-translational modification for regulating cellular activities, but site-specific modulation of phosphorylation is still challenging. Using three-dimensional NMR spectra, molecular dynamics simulations, and alanine mutations, we identified that the interaction network between pT69/pS70 and R106/R109 residues prevents the phosphorylation sites from exposure to phosphatase and subsequent dephosphorylation. A Bcl-2-dephosphorylation probe, S1-6e, was designed by installing a carboxylic acid group to a Bcl-2 inhibitor. The carboxyl group competitively disrupts the interaction network between R106/R109 and pT69/pS70 and subsequently facilitates Bcl-2 dephosphorylation in living cells. As a result, S1-6e manifests a more effective apoptosis induction in pBcl-2-dependent cancer cells than other inhibitors exhibiting a similar binding affinity for Bcl-2. We believe that targeting the allosteric pathways interconnecting the core-functional domain and the phosphorylation site can be a general strategy for a rational design of site-specific dephosphorylating probes, since the allosteric pathway has been discovered in a variety of proteins.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01290?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01290</a>.List of (φ, ψ) backbone angle pairs for residues R106-D111, diagram of the phosphorylation sites of Bcl-2, 3D NMR titration spectra of different Bcl-2 variants, crystal structure of Bcl-2 isoform 2 in complex with ABT-263 or ABT-199 analogue, plot of the RMSD values of the backbone atoms in MD, binding affinity curves of BH3 peptides or compounds with different Bcl-2 variants, binding affinity curves of compounds with Bcl-xl and Mcl-1, and LC–MS spectra of the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01290/suppl_file/jm0c01290_si_001.pdf">PDF</a>)MD-simulated structure of pBcl-2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01290/suppl_file/jm0c01290_si_002.pdb">PDB</a>)Docking-stimulated structure of S1-6e/Bcl-2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01290/suppl_file/jm0c01290_si_003.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01290/suppl_file/jm0c01290_si_004.csv">CSV</a>)This article has not yet been cited by other publications.

Dissecting the neuroprotective interaction between the BH4 domain of BCL-w and the IP3 receptor

L-3-n-Butylphthalide Protects HSPB8 K141N Mutation-Induced Oxidative Stress by Modulating the Mitochondrial Apoptotic and Nrf2 Pathways

Bcl-2 and IP3 compete for the ligand-binding domain of IP3Rs modulating Ca2+ signaling output

Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neuropathy

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Lysosomal Dysfunction in Schwann Cells is Involved in Bortezomib-Induced Peripheral Neurotoxicity

Characterizing the consensus residue specificity and surface of BCL-2 binding to BH3 ligands using the Knob-Socket model

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism.

Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-XL: Role of Non-Hot Spot Residues

Selective Covalent Targeting of Anti‐apoptotic BFL‐1 by a Sulfonium‐Tethered Peptide

Experimental Characterization of the Binding Affinities Between Proapoptotic BH3 Peptides and Antiapoptotic Bcl-2 Proteins

Targeting the Allosteric Pathway That Interconnects the Core-Functional Scaffold and the Distal Phosphorylation Sites for Specific Dephosphorylation of Bcl-2

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells

Binding modes of Bcl-2 homology 3 (BH3) peptides with anti-apoptotic protein A1 and redesign of peptide inhibitors: a computational study

BCL-X L –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors

Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics

Covalent inhibition of pro-apoptotic BAX

The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy

BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs